Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAetna Transanal Endoscopic Microsurgery Coverage |…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0747

    Transanal Endoscopic Microsurgery

    Customize your policy alerts

    Sign up for Aetna Policy 0747 alerts

    Get alerted when Policy 0747 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage of transanal endoscopic microsurgery (TEM) for members covered by Aetna, specifying indications considered medically necessary and those considered experimental/investigational.

    Policy Summary
    PayerAetna
    PolicyTransanal Endoscopic Microsurgery
    Policy CodePolicy 0747
    Change TypeRoutine review — no material changes
    Effective DateFeb 8, 2008
    Last ReviewOct 6, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain prior authorization for TEM (CPT 0184T) and document tumor size, location, T‑stage, and pathology to confirm selection criteria are met.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Medically necessary indications
    18Experimental/Investigational examples
    0184TNamed CPT code
    Aug 8, 2024Next review

    Coverage Criteria for Transanal Endoscopic Microsurgery (TEM)

    inv-01: Medically necessary indications

    Aetna considers transanal endoscopic microsurgery (TEM) medically necessary when ANY one of the following is met:

    Medically necessary indications: Benign rectal tumors (adenomas).
    threshold":"","note":""}
    Medically necessary indications: Small rectal carcinoids (less than 2 cm in diameter).< 2 cm in diameter

    inv-02: Experimental / investigational (not covered) indications

    Aetna considers TEM experimental and investigational for the following indications (examples, not all-inclusive):

    Experimental/Investigational indications: Advanced rectal cancer.
    Experimental/Investigational indications: Anorectal melanoma.
    Experimental/Investigational indications: Benign rectal strictures.
    Experimental/Investigational indications: Colorectal anastomotic stenosis.
    Experimental/Investigational indications: Colovesical fistula.
    Experimental/Investigational indications: Functional constipation.
    Experimental/Investigational indications: Giant villous adenoma of rectum.
    Experimental/Investigational indications: Megacolon.
    Experimental/Investigational indications: Rectal amyloidoma.
    Experimental/Investigational indications: Rectal gastro-intestinal stromal tumor (GIST).
    Experimental/Investigational indications: Rectal neuroendocrine tumor in advanced stages or with metastasis.
    Experimental/Investigational indications: Rectal prolapse and diverticula.
    Experimental/Investigational indications: Rectal schwannoma.
    Experimental/Investigational indications: Rectal ulcer syndrome.
    Experimental/Investigational indications: Recto-urinary fistula (e.g., recto-urethral fistula).
    Experimental/Investigational indications: Recto-vesical fistula.
    Experimental/Investigational indications: Retro-rectal (pre-sacral) tumors.
    Experimental/Investigational indications: Tubulovillous adenoma of the colon.

    inv-03: Appropriate indications for TEM

    Covered when ALL of the following typical selection criteria are met (per guideline summaries cited):

    TEM selection criteria: Lesion is T1 (early) rectal cancer; lesion size ≤ 3 cm; involves < 30% of rectal circumference; lesion within approximately 8 cm of the anal verge; lesion is mobile/non-fixed; pathology expected to be well- to moderately-differentiated with no lymphovascular or perineural invasion; no evidence of regional lymphadenopathy; full-thickness excision can achieve clear margins (eg, >3 mm or R0).see text

    Source: practice parameters and guideline assessments

    inv-04: Other supported indications

    Additional appropriate uses described in the literature:

    Other indications: Curative resection of benign tumors and carcinoid tumors; histopathologic staging in indeterminate cases; palliative resection for patients unfit or unwilling to undergo radical resection; completion surgery after incomplete endoscopic polypectomy for residual tumor.

    Reported in prospective and retrospective series.

    inv-05: Evidence-based use cases and cautions

    Situations and outcomes described in the evidence:

    TEM appropriate for: Large endoscopically unresectable adenomas and select well- or moderately-differentiated T1 rectal carcinomas may be treated with TEM; choice depends on careful patient selection and staging.

    Supported by low recurrence rates for adenomas and selective use in T1 cancers.

    TEM may be palliative or insufficient: For more advanced rectal cancers (T2 or greater) TEM should be considered palliative or experimental and completion radical surgery (TME) is advised when cure is intended.

    Higher local recurrence and lower unadjusted overall survival reported for TEM-only in pT2-3 compared to completion surgery.

    Alternative techniques may be preferred: Endoscopic submucosal dissection (ESD) may be preferred for large rectal epithelial tumors in some studies due to shorter procedure time and hospital stay and comparable outcomes.

    Comparative data cited (ESD vs TEM).

    inv-06: Coverage stance and clinical criteria

    Evidence and clinical findings described in the document support selective use of TEM/related techniques under these clinical scenarios and limitations:

    Indications supported by cited evidence: TEM is an established option for local excision of rectal adenomas and selected low-risk T1 rectal cancers; TEM-ESD has been reported as feasible for large adenomas and early rectal cancer with high en bloc resection rates in single-center series.

    Multiple retrospective series and TEM-ESD reports.

    Heterogeneous outcomes for fistulas: Use of TEM/TEO for recto-vesical or recto-urinary fistulas shows variable success: pooled literature reported ~77.8% healing, whereas a prospective series reported a 25% success rate for RUF, indicating caution in technique selection.

    Outcomes heterogeneous; prior diversion and scar tissue affect success.

    Novel techniques require validation: TEM-ESD and other novel TEM applications have promising single-center results (high en bloc and R0 rates, low morbidity) but require validation by well-designed studies before broad adoption.

    Evidence primarily retrospective and from single groups.

    ICD-10 diagnosis codes are used to align the indication for transanal endoscopic microsurgery (TEM) with the policy's covered indications. TEM is considered medically necessary when used for benign rectal tumors (adenomas), low‑risk Tis or T1 rectal carcinoma, or small rectal carcinoids (<2 cm in diameter). Representative ICD‑10 codes listed as covered when selection criteria are met include C20 (malignant neoplasm of rectum [low‑risk]), C7A.026 (malignant carcinoid tumor of the rectum), D01.1–D01.2 (carcinoma in situ of rectosigmoid junction/rectum), and D12.7–D12.9 (benign neoplasms of rectosigmoid/rectum/anus).

    High‑risk features and unfavorable tumor characteristics that make a lesion unsuitable for TEM include T‑stage above T1 (T2 or greater), evidence of regional lymphadenopathy, lymphovascular or perineural invasion, and poor (or poorly differentiated) histology. Guideline and workshop summaries recommend TEM only for carefully selected small, well‑ to moderately‑differentiated T1 tumors without nodal disease and limited circumferential involvement, because these high‑risk features are associated with higher recurrence after local excision.

    Giant rectal villous polyps (for example, those >8 cm in maximum dimension or circumferential lesions) are generally not amenable to TEM. These large lesions are associated with a high combined risk of dysplasia or malignancy (reported around 83% overall, with frank malignancy in about 33% of lesions >8 cm) and typically require formal radical oncologic resection rather than local endoluminal approaches.

    TEM (or TEO) repair for recto‑vesical or other recto‑urinary fistulas may be successful for simple fistulas; however, when the fistula tract is surrounded by wide, tough, fibrotic scar tissue from prior irradiation, HIFU, or multiple previous repair attempts, outcomes are poor and recurrence is common. In such heavily scarred or irradiated tissue, TEM repair is not recommended because closure failures and recurrences were observed in cases with fibrotic surroundings.

    This Clinical Policy Bulletin provides a general summary to assist in administering plan or program benefits but does not constitute a contract, an offer of coverage, or medical advice. Actual coverage determinations are governed by the terms of the member's plan or program and applicable contracts; providers should consult benefit documents and plan administrators for member‑specific coverage decisions.

    Use of TEM for indications other than the policy's specified medically necessary indications (benign rectal adenomas, low‑risk Tis/T1 rectal carcinoma, or small rectal carcinoids <2 cm) is considered experimental and investigational and therefore not medically necessary. Examples include advanced rectal cancer, anorectal melanoma, rectal GIST, rectal prolapse, recto‑urinary fistula, and other listed conditions.

    For more advanced rectal cancers (T2 or greater), TEM is generally considered experimental or palliative rather than curative. Multiple reviews and series indicate higher local recurrence after TEM‑only for pT2–pT3 tumors compared with completion radical resection (TME), and therefore TEM alone should not be used routinely when curative oncologic resection is intended.

    Comparative series show that TEM‑only management of pT2–pT3 rectal adenocarcinoma is associated with higher local recurrence and lower unadjusted overall survival compared with patients who underwent completion radical surgery. These findings support recommending completion total mesorectal excision when pathology shows more advanced invasion than anticipated after local excision.

    Reports of TEM/TEO for recto‑urinary fistula demonstrate variable outcomes. Pooled literature describes healing in a majority of cases in some series, but a prospective observational series of TEO/TEM repairs for recto‑urethral fistula reported a 25% success rate (2 of 8 repaired cases), with many patients requiring gracilis muscle interposition salvage procedures. These data indicate limited efficacy of TEM/TEO as the primary technique for complex RUF.

    Covered CPT code when selection criteria are met: 0184T — Excision of rectal tumor, transanal endoscopic microsurgical approach (TEMS), including muscularis propria (full thickness).

    A commonly cited threshold for suitability of rectal carcinoids for local excision/TEM is a maximum diameter of 2 cm; carcinoid tumors smaller than this are listed among the policy's medically necessary indications when other selection criteria are met.

    Coding and Diagnosis Codes

    Covered CPT Codes (if selection criteria met)CPTCovered
    0184TExcision of rectal tumor, transanal endoscopic microsurgical approach (ie, TEMS), including muscularis propria (ie, full thickness).
    ICD-10 Codes Covered if Selection Criteria MetICD-10Covered
    C20Malignant neoplasm of rectum [low-risk] [not covered for advanced rectal cancer] [giant villous adenoma].
    C7A.026Malignant carcinoid tumor of the rectum.
    D01.1Carcinoma in situ of rectosigmoid junction.
    D01.2Carcinoma in situ of rectum.
    D12.7Benign neoplasm of rectosigmoid junction.
    D12.8Benign neoplasm of rectum.
    D12.9Benign neoplasm of anus and anal canal.
    D3A.026Benign carcinoid tumor of the rectum.
    ICD-10 Codes Not Covered for Indications ListedICD-10Not Covered
    B57.32Megacolon in Chagas' disease.
    C43.51Malignant melanoma of anal skin.
    C49.A0Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    C49.A1Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    C49.A2Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    C49.A3Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    C49.A4Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    C49.A5Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    C49.A6Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    C49.A7Gastrointestinal stromal tumor [rectal gastro-intestinal stromal tumor].
    1–10 of 25
    1/3
    Rectal carcinoid size threshold
    Rectal carcinoid size thresholdLess than 2 cm in diameter
    Associated covered indicationSmall rectal carcinoids are listed as a medically necessary indication for TEM when <2 cm
    Coding notePolicy references ICD-10 code for malignant carcinoid (C7A.026) and benign carcinoid (D3A.026) in context of TEM coverage

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for transanal endoscopic microsurgery (TEM, CPT 0184T). Authorization decisions are contingent on the procedure meeting the plan's selection criteria for TEM and other benefit provisions.

    • Prior authorization required for CPT 0184T (Excision of rectal tumor, transanal endoscopic microsurgical approach).
    • Coverage contingent on meeting documented selection criteria and plan provisions.
    Documentation Required

    Staging and Need for Completion Surgery

    Preoperative clinical staging must be documented and the plan for completion radical surgery discussed when appropriate. If final pathology shows higher-stage disease (e.g., T2 or greater) or other high-risk features, completion total mesorectal excision should be considered and documented in the record and prior-authorization notes.

    • Document clinical stage (cTNM) and the imaging/staging modalities used (e.g., endorectal ultrasound, pelvic MRI).

    Background and Clinical Evidence

    Rectal cancers are staged using the TNM system (Tis–T4, N0–N3, M0–M1) and assigned stages 0–IV. Surgical decision‑making depends on tumor location, depth of invasion and clinical stage. TEM is a minimally invasive full‑thickness transanal excision technique primarily used for adenomas and selected early rectal carcinomas to preserve the rectum and avoid radical resection in appropriately selected patients.

    inv-05: Evidence-based use cases and cautions (additional placement for evidence narrative)

    Evidence-based use cases and cautions (additional narrative placement):

    Summary of evidence: Overall evidence supports TEM for adenomas and selected low-risk T1 cancers when careful preoperative staging and surgical technique can achieve full-thickness excision with clear margins; outcomes and applicability vary by lesion characteristics and prior treatments.

    See cited series and reviews for recurrence, morbidity, and comparative outcomes.

    Clinical cautions: Pre-existing fibrotic or irradiated tissue, unfavorable pathological features (eg, lymphovascular invasion, poor differentiation), and more advanced T-stage increase risk of recurrence or failure and often necessitate radical resection or alternative approaches.

    Reported in multiple series and systematic reviews.

    Definitions

    Low-risk T1 rectal carcinoma — definition
    DefinitionEarly invasive tumor confined to submucosa (T1) with favorable histology and low likelihood of nodal metastasis
    Selection featuresSuitable for local excision when well- to moderately-differentiated and without lymphovascular or perineural invasion
    ContextConsidered an indication for TEM when criteria for low-risk T1 (size, location, and absence of nodal disease) are met
    Transanal endoscopic microsurgery (TEM) — definition and CPT 0184T
    DefinitionEndoscopic full-thickness excision of a rectal tumor via a transanal endoscopic microsurgical approach (CPT 0184T)
    Procedure codingCPT code 0184T denotes excision of rectal tumor by TEM including muscularis propria (full thickness)

    Revision History

    2008-02-08effective_date

    Policy became effective.

    2023-10-06last_review

    Policy was last reviewed on October 6, 2023.

    2024-08-08next_reviewLatest

    Next scheduled review is August 8, 2024.

    Policy Summary
    PayerAetna
    PolicyTransanal Endoscopic Microsurgery
    Policy CodePolicy 0747
    Change TypeRoutine review — no material changes
    Effective DateFeb 8, 2008
    Last ReviewOct 6, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain prior authorization for TEM (CPT 0184T) and document tumor size, location, T‑stage, and pathology to confirm selection criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Transanal Endoscopic Microsurgery (TEM)Coding and Diagnosis CodesProvider Actions, Prior Authorization, and DocumentationBackground and Clinical EvidenceDefinitionsRevision History
    Cautions/contraindications: TEM repair of recto-vesical fistulas is less suitable when there is wide, tough scar tissue from prior irradiation, HIFU, or multiple prior repairs; such cases had recurrences.

    Reported series showed recurrences associated with fibrotic scar tissue.

    Adjuvant therapy consideration: For high-risk T1 rectal cancers treated with local excision, addition of adjuvant radiotherapy has been reported to reduce local recurrence in small series but should be considered only in highly selected cases.

    Retrospective data with small samples.

  1. Document counseling on the possibility and timing of completion total mesorectal excision if post‑operative pathology indicates more invasive disease.
  2. Documentation Required

    Clinical Documentation for Authorization

    Clinical documentation submitted with prior authorization requests must include indication for TEM and supporting preoperative data to allow clinical review and determination of appropriateness.

    • Primary indication (e.g., adenoma, Tis, T1 rectal cancer, rectal carcinoid) with corresponding ICD-10 code.
    • Preoperative staging results (endorectal ultrasound, pelvic MRI, CT as indicated).
    • Evidence of absence of nodal disease or documented rationale if nodal evaluation limited.
    Note

    Prior Authorization Guidance

    Prior authorization determinations are administrative and based on the Clinical Policy Bulletin; however, plan benefit provisions (member eligibility, benefit limits, and exclusions) govern final coverage decisions.

    • Clinical Policy Bulletin is a reference to assist administration of benefits — it does not guarantee coverage.
    • Authorizations do not override plan terms, member eligibility, or contract exclusions.
    Denial Risk

    Selection-Related Denial Risk

    Procedures for tumors that do not meet established TEM selection criteria (for example T2 or greater, >3 cm, involving >30% of circumference, fixed/non-mobile tumors, evidence of nodal disease) are at high risk for denial as experimental/investigational or not medically necessary.

    • High denial risk when tumor characteristics are inconsistent with covered TEM indications (e.g., T2+, >3 cm, >30% circumference, fixed tumor, lymphadenopathy).
    • Procedures performed for indications listed as experimental/investigational in the policy may be denied.
    Documentation Required

    Required Clinical Documentation

    Required clinical documentation elements for authorization and medical record retention include explicit tumor characteristics and pathology information used in outcome analyses and selection decisions.

    • Tumor size (maximum diameter) and percent circumferential involvement.
    • Distance from the anal verge (in cm) and tumor mobility.
    • T‑stage (clinical and, when available, pathologic), differentiation, and presence/absence of lympho‑vascular or perineural invasion.
    • Margins (expected and post‑operative), and whether excision was en bloc or piecemeal.
    Documentation Required

    Preoperative and Pathology Documentation

    Preoperative records and final pathology must be submitted and clearly documented because preoperative staging can understage tumors; final pathology may necessitate additional treatment recommendations.

    • Preoperative: imaging reports, endoscopic findings, biopsy results, and multidisciplinary discussion notes.
    • Postoperative: operative report, specimen orientation, margin status, pathologic T-stage, grade, and presence of lympho‑vascular invasion.
    Note

    Technique Selection and Sequencing

    Because TEM and alternative techniques (e.g., ESD, TEM‑ESD) have differing indications and outcomes, documentation should include the rationale for technique selection and consideration of less invasive options when appropriate.

    • Document why TEM was chosen over ESD or vice versa (lesion depth, size, location, expected en‑bloc resection rate, operator expertise).
    • Consider TEM‑ESD or referral to specialized centers when indicated by lesion characteristics.
    Documentation Required

    Pathology and Staging Documentation

    Final pathology and staging documentation are required to assess adequacy of local excision and to identify patients who need completion radical surgery; documentation is necessary because preoperative staging may underestimate invasion.

    • Submit full pathology report including pathologic T-stage, margin status (R0/R1), grade, and presence of adverse features.
    • Document counseling and recommendations for completion surgery if pathology reveals T2+ disease or other high‑risk features.
    Note

    Radiotherapy Consideration

    Guideline-level guidance recommends cautious, selective use of external beam radiotherapy (EBRT) as adjuvant or neoadjuvant therapy; EBRT should only be used in highly selected cases or within clinical trials and documented rationale must be provided when used to augment TEM.

    • If adjuvant or neoadjuvant radiotherapy is planned or given, include indication, regimen, timing relative to TEM, and multidisciplinary rationale.
    • EBRT should not be used indiscriminately in patients who are potentially surgically resectable.
    Note

    Refer to Policy Links for Documentation

    Providers should consult the policy review history, definitions, and Clinical Policy Bulletin notes for additional documentation instructions and administrative details when preparing authorization requests.

    • Refer to the policy's Review History and Definitions pages for terminology and procedural expectations.
    • Use the Clinical Policy Bulletin Notes as an administrative reference when submitting documentation for prior authorization.

    When selecting technique, comparative evidence indicates TEM achieves higher en‑bloc and R0 resection rates compared with endoscopic submucosal dissection (ESD) for large non‑pedunculated rectal lesions, but ESD may offer shorter procedure time and hospital stay in some series. Choice between TEM and alternative techniques (ESD or radical resection) should be based on lesion characteristics, ability to achieve clear margins, staging, and patient fitness for radical surgery.

    Clinical roleTEM is an alternative to conventional transanal excision for selected adenomas and early rectal cancers
    R0 resection — definition and margin context
    DefinitionAn R0 resection is a resection with clear (negative) margins — often cited as at least 1 mm (or a 3-mm negative margin in some guidelines)
    Margin contextAchieving R0 (negative) margins without tumor fragmentation is a pre-requisite for low recurrence rates after local excision/TEM
    Guideline noteNCCN guidance references a 3-mm negative margin for full-thickness excision in selected early rectal cancers
    Eligible TEM lesion — typical selection characteristics
    Size and circumferenceLesion typically ≤3 cm and involves <30% of rectal circumference
    LocationWithin approximately 8 cm of the anal verge (accessible by TEM)
    Pathology/stageT1 stage, well- to moderately-differentiated, without lymphovascular invasion or lymphadenopathy
    Transanal endoscopic microsurgery (TEM) — clinical technique
    Technique descriptionMinimally invasive transanal surgical technique for full-thickness excision of rectal lesions using a transanal endoscopic platform
    AdvantagesProvides magnified stereoscopic view, improved exposure, greater reach into middle/upper rectum, and preserves the rectum compared with radical resection
    IndicationsOriginally for rectal adenomas; extended to selected low-risk Tis/T1 rectal carcinomas as an organ-preserving option
    Total mesorectal excision (TME) — definition
    DefinitionTotal mesorectal excision (TME) is the standard radical surgical procedure for many stage I–II rectal cancers providing oncologic resection of the mesorectum
    Clinical impactTME is usually curative but may have substantial quality-of-life impacts (e.g., permanent colostomy, bowel/bladder/sexual dysfunction)
    Role relative to TEMTME is recommended for tumors with high-risk features or more advanced stage when curative radical resection is intended
    TEM-ESD — hybrid technique definition
    DefinitionA hybrid method that combines TEM's rigid transanal platform and ergonomics with the submucosal dissection approach of endoscopic submucosal dissection (ESD)
    PurposeDesigned to achieve en bloc local resection while preserving deeper rectal wall and mesorectal structures
    Evidence statusFeasibility, safety, and outcomes are reported in single-group retrospective series; broader validation is pending
    TEO — Transanal endoscopic operation
    DefinitionTransanal endoscopic operation (TEO) is a minimally invasive transanal endoscopic approach analogous to TEM used to access and repair anorectal pathology
    Clinical applicationTEO/TEM has been used for repair of recto-urethral and recto-urinary fistulas, sometimes with biological mesh interposition
    Outcome cautionProspective series report limited success in RUF repair (25% success in one series), suggesting careful case selection

    This Clinical Policy Bulletin is provided to assist in administration of plan benefits and to document the policy's scope and review history. It does not alter plan contract terms. Providers should be aware of the policy's review dates and consult member benefit documents and the policy's review/history pages for administrative details and any updates.